Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Alemtuzumab benefits hard-to-treat MS patients
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia.
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
Neuromyelitis optica: Evaluation of 871 attacks and 1153 treatment courses.
Raxone®/Catena® (idebenone)
Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
3 Blockbuster Drugs Losing Patent Protection in 2013's Final Months
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.
Serum from interferon-β-1b-treated patients with early multiple sclerosis stabilizes the blood-brain barrier in vitro.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Complex antibody profiling to predict clinical outcome in childhood ADS.
Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis.

Pages